



**Understanding Cost-Effectiveness Analysis in Health Care (313.790.81)**  
**Instructor: Kevin D. Frick, PhD**

Live Talk	Associated Readings
Solidifying underlying concepts	
Solidifying concepts from recommendations	Haddix Chapter 9 & Discussion I
Discussion of decision rules and how the rules apply to cancer treatment	Haddix Chapters 7,8, and 10 & Discussion II
Discussion of the concepts behind QALYs, implications of using QALYs, and how QALYs were calculated in the Discussion III piece	Haddix Chapter 5 & Discussion III
Solidifying cost concepts	Haddix Chapters 4 & 6
Any outstanding issues	Discussion IV-VIII

***Reading List***

Book

Haddix AC, Teutsch SM, Corso PS (eds). *Prevention Effectiveness: A Guide to Decision Analysis and Economic Evaluation: Second Edition*. 2002. Oxford University Press.

Discussion I

Phillips KA, Chen JL. Impact of the U.S. panel on cost-effectiveness in health and medicine. *Am J Prev Med*. 2002; 22(2): 98-105.

Saha S, Hoerger TJ, Pignone MP, Teutsch SM, Helfand M, Mandelblatt JS; Cost Work Group, Third US Preventive Services Task Force. The art and science of incorporating cost effectiveness into evidence-based recommendations for clinical preventive services. *Am J Prev Med*. 2001; 20(3 Suppl): 36-43.

Discussion II

Ramsey SD, Moinpour CM, Lovato LC, Crowley JJ, Grevstad P, Presant CA, Rivkin SE, Kelly K, Gandara DR. Economic analysis of vinorelbine plus cisplatin versus paclitaxel plus carboplatin for advanced non-small-cell lung cancer. *J Natl Cancer Inst*. 2002; 94(4): 291-7.

Ramsey SD, Kessler LG. Does economics matter when treating advanced non-small cell lung cancer? *Oncologist*. 2002; 7(3): 179-80.

Roberts TG Jr, Lynch TJ Jr, Chabner BA. Choosing chemotherapy for lung cancer based on cost: not yet. *Oncologist*. 2002; 7(3): 177-8.

Discussion III

Schackman BR, Freedberg KA, Weinstein MC, Sax PE, Losina E, Zhang H, Goldie SJ. Cost-effectiveness implications of the timing of antiretroviral therapy in HIV-infected adults. *Arch Intern Med*. 2002; 162(21): 2478-86.

Discussion IV

Mahadevia PJ, Fleisher LA, Frick KD, Eng J, Goodman SN, Powe NR. Lung cancer screening with helical computed tomography in older adult smokers: a decision and cost-effectiveness analysis. *JAMA*. 2003; 289(3): 313-22.

Discussion V

Samsa GP, Reutter RA, Parmigiani G, Ancukiewicz M, Abrahamse P, Lipscomb J, Matchar DB. Performing cost-effectiveness analysis by integrating randomized trial data with a comprehensive decision model: application to treatment of acute ischemic stroke. *J Clin Epidemiol.* 1999; 52(3): 259-71.

Discussion VI

Lieu TA, Ray GT, Black SB, Butler JC, Klein JO, Breiman RF, Miller MA, Shinefield HR. Projected cost-effectiveness of pneumococcal conjugate vaccination of healthy infants and young children. *JAMA.* 2000; 283(11): 1460-8.

Discussion VII

Lee PY, Matchar DB, Clements DA, Huber J, Hamilton JD, Peterson ED. Economic analysis of influenza vaccination and antiviral treatment for healthy working adults. *Ann Intern Med.* 2002; 137(4): 225-31.